Updated with stock price.
) -- Shares of
more than doubled Friday morning after the company released promising new data on its hepatitis C drug candidate.
The Inhibitex drug INX-189 belongs to the same "nucleoside" class of potent oral hepatitis C drugs as
heralded PSI-7977. The difference, of course, is that Inhibitex's market value is $300 million, or at least it was going into Friday's trading. Pharmasset's market value is close to $6 billion.
Investors are hoping that the magical Hep C pixie dust that has made Pharmasset the best-performing biotech stock this year will work its charms on Inhibitex as well.
Inhibitex shares soared 127% to $9.01 in mid-day trading after the company reported a 4.25 log drop in Hep C viral load after 7 days of treatment with a 200 mg dose of INX-189 in treatment-naive patients. No serious adverse events were reported.
That result is comparable to the viral load decline demonstrated by Pharmasset's PSI-7977 in an earlier study.
Nucleoside or "nucs" have become the belles of the Hep C drug ball because of their potential as a backbone of future all-oral combination Hep C therapy. Pharmasset's nuc PSI-7977 has garnered the most attention, but companies like Inhibitex and
are also developing their own Hep C nucs.
Pharmasset shares were down 4% to $74.80 in early Friday trading, likely due to competitive concerns stemming from the INX-189 data.
In Friday's release, Inhibitex said it was moving forward with new studies of INX-189 including one in combination with an another undisclosed direct-acting antiviral Hep C drug.
The new Inhibitex data on INX-189 comes on the eve of the American Association for the Study of Liver Disease (AASLD) annual meeting, which will feature important presentations of new hepatitis C drug research.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on